Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 22;17(1):640.
doi: 10.1186/s12879-017-2750-9.

Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study

Sepiso K Masenga  1   2 , Harrison Mubila  3 , Benson M Hamooya  4   5
Affiliations

Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study

Sepiso K Masenga et al. BMC Infect Dis. .

Abstract

Background: Since the recent introduction of GeneXepert for the detection of Tuberculosis (TB) drug resistance mutations in both primary resistance and acquired resistance in Zambia, little has been documented in literature on the issue of rifampicin resistance especially in the face of a high National TB burden. The study aimed to determine the prevalence of rifampicin resistance in tuberculosis patients at Livingstone Central Hospital for the year 2015.

Methods: This was a cross sectional study conducted at Livingstone Central Hospital where we reviewed 152 records (from January 1, 2015 to 31st December, 2015) involving patients who presented with clinically suspected TB or documented TB, whose samples were sent to the laboratory for GeneXpert Mycobacterium tuberculosis/rifampicin testing. Statistical evaluations used a one-sample test of proportion and Fisher's exact test.

Results: The age of participants ranged from 8 months to 73 years old (median = 34). Of the participants with complete data on gender, 99 (66%) and 52 (34%) were males and females respectively. The TB co-infection with HIV prevalence was 98.3% (p < 0.001). Prevalence of rifampicin resistance was 5.9% and there was no statistical significant difference between being male or female (p = 0.721).

Conclusion: We were able to show from our study, evidence of rifampicin resistance at Livingstone Central Hospital. Hence, there was need for further in-depth research and appropriate interventions (i.e close follow-up and patient care for drug resistance positive patients).

Keywords: GeneXpert; Mycobacterium tuberculosis; Rifampicin resistance.

PubMed Disclaimer

Conflict of interest statement

Authors’ information

SKM is a Biomedical scientist (BSc.) and a Clinical Biochemist (MSc.) currently working at Livingstone Central Hospital Laboratory, in the Research section. BMH is a Biomedical scientist (BSc.) and an Epidemiologist (MSc.) currently working at Livingstone Central Hospital Laboratory, in the Research section. HM is a student pursuing a diploma at Chikankata College of Biomedical Sciences.

Ethics approval and consent to participate

This study was nested in a study that was conducted in 2015 and approved by the University of Zambia Research Ethics committee (Assurance No. FWA00000338 IRB00001131 of IORG0000774, REF No. 007–10-14 obtained on the 12th of December, 2014).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Kapata N, Chanda-Kapata P, O’Grady J, Schwank S, Bates M, Mukonka V, et al. Trends of Zambia’s tuberculosis burden over the past two decades. Tropical Med Int Health. 2011;16(11):1404–1409. doi: 10.1111/j.1365-3156.2011.02849.x. - DOI - PubMed
    1. World Health Organization, others. What is DOTS?: A guide to understanding the WHO-recommended TB Control Strategy Known as DOTS. 1999; Available from: http://apps.who.int/iris/bitstream/10665/65979/1/WHO_CDS_CPC_TB_99.270.pdf
    1. Boakye-Appiah JK, Steinmetz AR, Pupulampu P, Ofori-Yirenkyi S, Tetteh I, Frimpong M, et al. High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. International Journal of Mycobacteriology. 2016;5(2):226–230. doi: 10.1016/j.ijmyco.2016.02.004. - DOI - PubMed
    1. Dagnra AY, Mlaga KD, Adjoh K, Kadanga E, Disse K, Adekambi T. Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF. New Microbes and New Infections. 2015;8:24–27. doi: 10.1016/j.nmni.2015.09.001. - DOI - PMC - PubMed
    1. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2005;43(8):3699–3703. doi: 10.1128/JCM.43.8.3699-3703.2005. - DOI - PMC - PubMed

MeSH terms